In ₹ Crore except Per Share Latest Annual | NEPHROPLUS FY26 | KRSNAA FY26 | SURAKSHA FY26 | HEALTHX FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | 88.35× | ◆ 18.00× | 52.78× | 824.32× | 52.78× +67% | |
| P/B | 6.73× | 1.86× | 6.98× | ◆ 1.27× | 1.86× +261% | |
| EV/EBITDA | 32.18× | ◆ 11.01× | 17.79× | — | 14.40× +123% | |
| Market Cap | ₹7,517 Cr | ₹1,828 Cr | ₹1,699 Cr | ₹970 Cr | ₹1,699 Cr +342% | |
| Growth | ||||||
| Revenue CAGR 3Y | — | ◆ 16.63% | — | 8.26% | 12.45% | |
| Revenue CAGR 5Y | — | — | — | 19.20% | 19.20% | |
| Net Income CAGR 3Y | — | 17.76% | — | — | 17.76% | |
| Revenue YoY (latest Q) | — | 22.05% | 20.75% | ◆ 49.73% | 22.05% | |
| Net Income YoY (latest Q) | — | -19.34% | ◆ 40.00% | -92.53% | -19.34% | |
| Profitability | ||||||
| EBITDA Margin | 22.72% | 27.42% | ◆ 30.73% | -3.95% | 27.42% -17% | |
| Net Income Margin | 7.69% | ◆ 13.13% | 10.12% | -0.11% | 10.12% -24% | |
| Return on Common Equity | 6.88% | 10.35% | ◆ 13.22% | 0.15% | 10.35% -34% | |
| Return on Capital Employed | 11.63% | 7.84% | ◆ 13.89% | — | 10.87% +7% | |
| Return on Assets | 5.22% | 5.56% | ◆ 7.01% | -0.15% | 5.56% -6% | |
| Credit & Quality | ||||||
| Total Debt/Equity | 0.07× | 0.55× | ◆ 0.01× | — | 0.28× -75% | |
| Interest Coverage | 2.26× | 3.53× | ◆ 4.30× | -75.12× | 3.53× -36% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹999 Cr | ₹773 Cr | ₹310 Cr | ₹1,319 Cr | ₹773 Cr +29% | |
| Net Income | ₹76.8 Cr | ₹101 Cr | ₹31.4 Cr | −₹1.4 Cr | ₹31.4 Cr +145% | |
| Total Assets | ₹1,471 Cr | ₹1,824 Cr | ₹448 Cr | ₹936 Cr | ₹936 Cr +57% | |
| EPS | ₹8.48 | ₹31.3 | ₹6.18 | ₹0.37 | ₹6.18 +37% | |
| Book Value per Share | ₹111.27 | ₹302.23 | ₹46.75 | ₹240.57 | ₹240.57 -54% | |